The latest biotech news - Labiotech.eu

Home News and Trends Page 287

Latest Posts

headphones music tinnitus nito fi

News and Trends 7 Oct 2016

Do we hear a Tinnitus Cure? This techno-loving CEO might have one…

It’s Friday, and here in Berlin, we’re ready for the club. A German company, Sonormed, is developing an app that can reduce the consequent ringing in our ears. Sonormed’s co-founder and CEO, Jörg Land, loves techno, and he started a company to help his fellow beat lovers with their common affliction of tinnitus. His soon-to-be […]

October 7, 2016 - 3 minutesmins - By Evelyn Warner

scissors couture optimarc fi

News and Trends 7 Oct 2016

Meet the ‘Haut-Couturiers’ of Bioengineering

It’s time to ride the slopes and land in the French alpine capital, Grenoble, to meet our Biotech of the week, BGene Genetics. This start-up is changing the bug factory sector! BGene has developed a method to edit the chromosomes of a bug to produce proteins rather than inserting a plasmid, and this proprietary technology […]

October 7, 2016 - 3 minutesmins - By Jerome Topsent

shutterstock 175106708

News and Trends 7 Oct 2016

Will SynBio replace the French Wine Industry?

Ava Winery is creating cheap, sustainable and customizable wine without grapes, yeast or fermentation. The company plans to commercialize its first product in the coming months, will they be able to steal customers from the most famous French wine companies? Ava Winery claims that 90% of tasters cannot tell its prototype apart from traditional wine. The […]

October 7, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

liver bluebay fi

News and Trends 6 Oct 2016

NASH Maverick continues Rampage with €34M Cash Injection

Genfit just added €34M to its cash pile through private placement to bankroll the development of its succeeding lead candidate, Elafibranor. Genfit has had a good year. Earlier this year, the company enrolled its first patient in Phase III clinical trails for Non-Alcoholic Stato-Hepatitis (NASH), and last month, it launched a new non-invasive diagnostic program. It’s […]

October 6, 2016 - 2 minutesmins - By Evelyn Warner

shutterstock 419773786

News and Trends 6 Oct 2016

New UK Hero Will Fight Against Non-Small Cell Lung Cancer

Achilles Therapeutics was born yesterday in the UK with a €15M funding round. The company will focus on the development of personalized neo-antigentherapies for non-small lung cancer. The newborn Achilles Therapeutics made its debut yesterday with a splashy fundraising round and a licensing agreement. The startup has exclusive rights to develop and commercialize any neo-antigen technology that […]

October 6, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

oxford Keith Barnes fi

News and Trends 6 Oct 2016

A new Immuno-Oncology biotech’s Small Molecule hits the Clinic

Since we interviewed Karus Therapeutics last year, the company has come quite a way! The Oxford-based biotech has just sent its first drug to the clinic. We first met Karus Therapeutics a year ago to talk about their small molecule therapies for cancer and inflammatory disease. The company has entered the immuno-oncology fray and is developing a […]

October 6, 2016 - 2 minutesmins - By Evelyn Warner

ADVERTISEMENT

shutterstock 88628866

News and Trends 5 Oct 2016

€365M deal for a Danish ‘DNA barcode’ Drug Screening Platform

The giant Amgen has offered Nuevolution €365M to develop oncology and neuroscience drugs. The small Danish Biotech claims to count with an unprecedented drug discovery platform that can screen billions of compounds way faster and at a lower cost than the big players. Despite its small size, Nuevolution is experienced in collaborating with big Pharma like Merck, Novartis, […]

October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

obesity microbiome research kings college

News and Trends 5 Oct 2016

New Link found between the Microbiome and “Genetic Obesity”

Researchers at King’s College London have found a new link between gut microbiome diversity (or, more specifically, the lack of it) and a particularly troubling kind of obesity. This finding could also help explain the inheritability of this disease. The explosive growth of the Microbiome field promises a whole new type of therapies, but this […]

October 5, 2016 - 3 minutesmins - By Denise Neves Gameiro

shutterstock 340501226

News and Trends 5 Oct 2016

New Psoriasis Antibody Therapy puts pressure on Best-Seller drug Humira

New results from a Phase III trial show that guselkumab, an antibody therapy for the autoimmune disease plaque psoriasis, is performing better than the number one best-seller drug Humira (adalimumab) from AbbVie. The new drug is expected to be commercially available as early as 2018. Since MorphoSys licensed guselkumab to Janssen Biotech, in 2007, the drug has been performing […]

October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

crispr dna editing lightspring fi

News and Trends 4 Oct 2016

CRISPR will Win the Nobel Prize, but When? Not this year…

Nobel Prize week has kicked off with the announcement of Physiology and Medicine recipient: it wasn’t the CRISPR crowd, but Yoshinori Ohsumi for his work on autophagy. As Derek Lowe puts it, CRISPR “is absolutely, positively going to win a Nobel; the only question is when.” Well, it didn’t manage last year, nor this year. […]

October 4, 2016 - 2 minutesmins - By Evelyn Warner

CI Photos DNA FI

News and Trends 4 Oct 2016

A Secretive new Oncology Biotech has made a Dramatic Debut

Carrick Therapeutics has burst onto the oncology scene with a massive round of fundraising, reeling in almost €100M to become Europe’s cancer leader. Since its foundation last year, oncology upstart Carrick Therapeutics has mostly stayed off the radar. That changed yesterday, when it announced a splashy fundraising round of €85M ($95M) to propel it to the top of […]

October 4, 2016 - 3 minutesmins - By Evelyn Warner

shutterstock 490429708

News and Trends 4 Oct 2016

One Step Closer to an HIV Cure That Can Eliminate the Latent Virus

HIV has completely disappeared from the blood of a patient in clinical trials. The new HIV treatment that can target the virus even in its dormant state by activating latent infected cells and could possibly become the first HIV cure available. These initial results show that the new therapy, developed in the UK, may be effective in curing HIV. One of 50 […]

October 4, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT